Gaj Pawel, Habior Andrzej, Mikula Michal, Ostrowski Jerzy
Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education at the Maria Skłodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw, Poland.
BMC Med Genet. 2008 Aug 21;9:81. doi: 10.1186/1471-2350-9-81.
Numerous papers have addressed the association of mutations and polymorphisms of susceptibility genes with autoimmune inflammatory disorders. We investigated whether polymorphisms that confer susceptibility to Crohn's disease could be classified also as predisposing factors for the development of primary sclerosing cholangitis and primary biliary cirrhosis in Polish patients.
The study included 60 patients with CD, 77 patients with PSC, of which 61 exhibited IBD (40 UC, 8 CD, and 13 indeterminate colitis), and 144 patients with PBC. All the patients were screened against Crohn's disease associating genetic polymorphisms. The polymorphisms were chosen according to previously confirmed evidence for association with Crohn's disease, including Pro268Ser, Arg702Trp, Gly908Arg and 1007fs in NOD2/CARD15, Leu503Phe/-207G>C in SLC22A4/OCTN1/SLC22A5/OCTN2, Arg30Gln in DLG5, Thr300Ala in ATG16L1, and Arg381Gln, His3Gln and exon-3'UTR in IL23R. Genotyping was carried out using TaqMan SNP genotyping assays.
We confirmed a strong association between three NOD2/CARD15 gene variants (Pro268Ser, OR = 2.52, 95% CI = 1.34-4.75); (Arg702Trp, OR = 6.65, 95% CI = 1.99-22.17); (1007fs, OR = 9.59, 95% CI = 3.94-23.29), and a weak association between both the protective OCTN1/OCTN2 CC haplotype (OR = 0.28, 95% CI = 0.08-0.94), and a variant of ATG16L1 gene (Thr300Ala, OR = 0.468, 95% CI = 0.24-0.90) with Crohn's disease. In contrast, none of the polymorphisms exhibited association with susceptibility to primary sclerosing cholangitis and primary biliary cirrhosis, including a group of primary sclerosing cholangitis patients with concurrent IBD.
Although the clinical data indicate non-random co-occurrence of inflammatory bowel disease and primary sclerosing cholangitis, consistently with the previously published studies, no genetic association was found between the genetic variants predisposing to Crohn's disease and hepatobiliary autoimmune disorders. However, since estimation of genetic variant disproportion is limited by sample size, these negative results may also indicate that eventually shared genetic predispositions are too little to be captured by small patient groups.
众多论文探讨了易感基因的突变和多态性与自身免疫性炎症性疾病的关联。我们研究了在波兰患者中,那些使个体易患克罗恩病的多态性是否也可被视为原发性硬化性胆管炎和原发性胆汁性肝硬化发病的易感因素。
该研究纳入了60例克罗恩病患者、77例原发性硬化性胆管炎患者(其中61例患有炎症性肠病,包括40例溃疡性结肠炎、8例克罗恩病和13例未定型结肠炎)以及144例原发性胆汁性肝硬化患者。所有患者均针对与克罗恩病相关的基因多态性进行筛查。这些多态性是根据先前已证实的与克罗恩病关联的证据选取的,包括NOD2/CARD15基因中的Pro268Ser、Arg702Trp、Gly908Arg和1007fs突变,SLC22A4/OCTN1/SLC22A5/OCTN2基因中的Leu503Phe/-207G>C突变,DLG5基因中的Arg30Gln突变,ATG16L1基因中的Thr300Ala突变,以及IL23R基因中的Arg381Gln、His3Gln和外显子3'非翻译区突变。采用TaqMan SNP基因分型检测法进行基因分型。
我们证实了NOD2/CARD15基因的三个变体(Pro268Ser,OR = 2.52,95%CI = 1.34 - 4.75);(Arg702Trp,OR = 6.65,95%CI = 1.99 - 22.17);(1007fs,OR = 9.59,95%CI = 3.94 - 23.29)与克罗恩病之间存在强关联,同时保护性的OCTN1/OCTN2 CC单倍型(OR = 0.28,95%CI = 0.08 - 0.94)以及ATG16L1基因的一个变体(Thr300Ala,OR = 0.468,95%CI = 0.24 - 0.90)与克罗恩病之间存在弱关联。相比之下,这些多态性均未显示出与原发性硬化性胆管炎和原发性胆汁性肝硬化的易感性相关,包括一组同时患有炎症性肠病的原发性硬化性胆管炎患者。
尽管临床数据表明炎症性肠病和原发性硬化性胆管炎并非随机同时出现,但与先前发表的研究一致,在易患克罗恩病的基因变体与肝胆自身免疫性疾病之间未发现遗传关联。然而,由于基因变体比例的估计受样本量限制,这些阴性结果也可能表明最终共同的遗传易感性过小,以至于小样本患者群体无法检测到。